Type:Tablet
Generic Name:Trimetazidine Dihydrochloride
Manufacturer:Sharif Pharmaceuticals Ltd.
Price:৳5.00
Ischaemic heart disease, Angina pectoris, Coronary heart disease
Should be taken with food.
Oral Angina pectoris Adult: 40-60 mg daily in 2-3 divided doses. Modified-release tab: 35 mg bid.
Renal impairment: CrCl (ml/min) Dosage Recommendation <30 Contraindicated. 30-60 20 mg bid. Modified-release: 35 mg once daily.
Hypersensitivity to Trimetazidine Dihydrochloride.
Trimetazidine is a cellular acting anti-ischaemic agent. It has 3 main properties by which it acts as a cytoprotective agent. It inhibits the anaerobic glycolysis and fatty acid metabolism, thus allowing only aerobic glycolysis. This action helps to restore the energy balance in the cell. It inhibits acidosis and free radical accumulation in the cell. All these action help the cell to restore the normal ionic and metabolic balance.
Moderate renal impairment (CrCl 30-60 mL/min). Pregnancy. Patient Counselling May cause dizziness and drowsiness, if affected, do not drive or operate machinery. Although teratological studies have not shown any drug related adverse effects on the course and outcome of pregnancy, the use in pregnant women is not recommended. It is not known whetherTrimetazidine passes into breast milk or not. This medication should be used while breast feeding only if the potential benefits outweigh risks to the nursing infants.
Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, nausea, vomiting, pruritus, rash, urticaria, asthenia. Rarely, tachycardia, palpitations, extrasystoles, orthostatic hypotension, arterial hypotension, flushing.
MAOIs, nifedipine. May potentiate the effects of other antianginals.
